Strategic Investment Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Strategic Investment Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-457	Closed	-$219K	–	190
2023 Q1	$219K	Buy	+457	New	+$214K	0.04%	224
2022 Q3	–	Sell	-1,380	Closed	-$683K	–	180
2022 Q2	$683K	Buy	1,380 +65	+5%	+$33.9K	0.14%	121
2022 Q1	$741K	Sell	1,315 -18	-1%	-$10.9K	0.14%	130
2021 Q4	$1.01M	Sell	1,333 -27	-2%	-$20.2K	0.19%	106
2021 Q3	$1.01M	Buy	1,360 +11	+0.8%	+$8.24K	0.22%	97
2021 Q2	$869K	Buy	1,349 +93	+7%	+$56.6K	0.2%	107
2021 Q1	$717K	Buy	1,256 +250	+25%	+$148K	0.19%	100
2020 Q4	$586K	Buy	+1,006	New	+$573K	0.17%	110

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Strategic Investment Advisors's BIO Position: Q2 2023 in Review

Strategic Investment Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2023, closing a stake of 457 shares — an estimated $219K sold.

Strategic Investment Advisors first reported a position in BIO in Q4 2020 and held it in 8 quarters. The position peaked at $1.01M in Q3 2021. 468 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

Strategic Investment Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q2 2023 after selling out during the quarter.
Strategic Investment Advisors sold 457 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $219K.
Strategic Investment Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and held it in 8 quarters.
Strategic Investment Advisors's Bio-Rad Laboratories Class A position peaked at $1.01M in Q3 2021.
468 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on Strategic Investment Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.